| Literature DB >> 28118037 |
Tipattaraporn Panich1, Khajornsak Tragoolpua2,3,4, Supansa Pata3,5, Chatchai Tayapiwatana3,4,5, Nutjeera Intasai1,3,4.
Abstract
Overexpression of extracellular matrix metalloproteinase inducer (EMMPRIN) accelerates tumor invasion and metastasis via activation of matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA) expression. The authors were interested in whether the scFv-M6-1B9 intrabody against EMMPRIN that retains EMMPRIN in endoplasmic reticulum could be a potential tool to suppress cervical cancer invasion through inhibition of uPA. The chimeric adenoviral vector Ad5/F35-scFv-M6-1B9 was transferred into human cervical carcinoma HeLa cells to produce the scFv-M6-1B9 intrabody against EMMPRIN. Cell surface expression of EMMPRIN, the membrane-bound uPA, the enzymatic activity of secreted uPA, and the invasion ability were analyzed. The scFv-M6-1B9 intrabody successfully diminished the cell surface expression of EMMPRIN and the membrane-bound uPA on HeLa cells. uPA activity from tissue culture media of EMMPRIN-downregulated HeLa cells was decreased. The invasion ability of HeLa cells harboring scFv-M6-1B9 intrabody was also suppressed. These results suggested that the scFv-M6-1B9 intrabody might represent a potential approach for invasive cervical cancer treatment. The application of scFv-M6-1B9 intrabody in animal experiments and preclinical studies would be investigated further.Entities:
Keywords: EMMPRIN; cervical cancer; intrabody; invasion; scFv; uPA
Mesh:
Substances:
Year: 2017 PMID: 28118037 DOI: 10.1089/cbr.2016.2126
Source DB: PubMed Journal: Cancer Biother Radiopharm ISSN: 1084-9785 Impact factor: 3.099